von Willebrand factor cleaving protease and vWF measurements in physiological and pathologic conditions
. | vWF protease . | vWF:Ag . | vWF:CB . | vWF:CB/Ag . |
---|---|---|---|---|
Physiologic conditions | ||||
Healthy adults | ||||
20-35 y (n = 52) | 100 ± 32 | 108 ± 31 | 105 ± 29 | 0.99 ± 0.21 |
(40-170) | (54-172) | (60-186) | (0.66-1.39) | |
36-50 y (n = 48) | 100 ± 29 | 113 ± 44 | 106 ± 33 | 1.02 ± 0.26 |
(46-168) | (45-215) | (42-194) | (0.68-1.52) | |
51-65 y (n = 38) | 101 ± 29 | 112 ± 40 | 117 ± 42 | 1.08 ± 0.34 |
(57-157) | (54-235) | (54-256) | (0.59-1.86) | |
> 65 y (n = 39) | 87 ± 26 | 141 ± 48* | 136 ± 44* | 0.96 ± 0.25 |
(40-162) | (52-228) | (50-228) | (0.48-1.65) | |
Healthy newborns (n = 26) | 52 ± 17* | 136 ± 51† | 162 ± 76* | 1.2 ± 0.44‡ |
(25-118) | (52-286) | (62-362) | (0.83-2.6) | |
Pregnant women | ||||
1st trimester (n = 18) | 94 ± 31 | 151 ± 65† | 149 ± 43† | 1.12 ± 0.43 |
(40-160) | (62-318) | (96-264) | (0.53-2.12) | |
2nd trimester (n = 19) | 64 ± 34* | 158 ± 39* | 161 ± 46* | 1.02 ± 0.19 |
(22-135) | (90-247) | (78-274) | (0.58-1.22) | |
3rd trimester (n = 32) | 64 ± 15* | 215 ± 94* | 173 ± 69* | 0.89 ± 0.34 |
(38-102) | (84-422) | (84-480) | (0.51-1.80) | |
Pathologic conditions | ||||
Liver cirrhosis (n = 42) | 46 ± 33* | 766 ± 424* | 589 ± 268* | 0.86 ± 0.33 |
(6-146) | (238-1760) | (183-1080) | (0.31-2.06) | |
Chronic renal insufficiency (n = 63) | 74 ± 30* | 186 ± 79* | 146 ± 72 | 0.83 ± 0.3* |
(15-140) | (66-504) | (52-416) | (0.31-1.9) | |
Acute inflammatory states (n = 15) | 40 ± 12* | 310 ± 140* | 269 ± 90* | 0.94 ± 0.27 |
(15-59) | (123-611) | (120-424) | (0.42-1.6) | |
Major surgery (n = 24) | ||||
Before | 83 ± 27 | 142 ± 53 | 162 ± 77 | 1.16 ± 0.36 |
(48-141) | (72-293) | (60-392) | (0.44-1.39) | |
After 4 days | 58 ± 27* | 201 ± 95* | 185 ± 75‡ | 0.98 ± 0.39† |
(18-131) | (95-300) | (72-369) | (0.90-1.62) |
. | vWF protease . | vWF:Ag . | vWF:CB . | vWF:CB/Ag . |
---|---|---|---|---|
Physiologic conditions | ||||
Healthy adults | ||||
20-35 y (n = 52) | 100 ± 32 | 108 ± 31 | 105 ± 29 | 0.99 ± 0.21 |
(40-170) | (54-172) | (60-186) | (0.66-1.39) | |
36-50 y (n = 48) | 100 ± 29 | 113 ± 44 | 106 ± 33 | 1.02 ± 0.26 |
(46-168) | (45-215) | (42-194) | (0.68-1.52) | |
51-65 y (n = 38) | 101 ± 29 | 112 ± 40 | 117 ± 42 | 1.08 ± 0.34 |
(57-157) | (54-235) | (54-256) | (0.59-1.86) | |
> 65 y (n = 39) | 87 ± 26 | 141 ± 48* | 136 ± 44* | 0.96 ± 0.25 |
(40-162) | (52-228) | (50-228) | (0.48-1.65) | |
Healthy newborns (n = 26) | 52 ± 17* | 136 ± 51† | 162 ± 76* | 1.2 ± 0.44‡ |
(25-118) | (52-286) | (62-362) | (0.83-2.6) | |
Pregnant women | ||||
1st trimester (n = 18) | 94 ± 31 | 151 ± 65† | 149 ± 43† | 1.12 ± 0.43 |
(40-160) | (62-318) | (96-264) | (0.53-2.12) | |
2nd trimester (n = 19) | 64 ± 34* | 158 ± 39* | 161 ± 46* | 1.02 ± 0.19 |
(22-135) | (90-247) | (78-274) | (0.58-1.22) | |
3rd trimester (n = 32) | 64 ± 15* | 215 ± 94* | 173 ± 69* | 0.89 ± 0.34 |
(38-102) | (84-422) | (84-480) | (0.51-1.80) | |
Pathologic conditions | ||||
Liver cirrhosis (n = 42) | 46 ± 33* | 766 ± 424* | 589 ± 268* | 0.86 ± 0.33 |
(6-146) | (238-1760) | (183-1080) | (0.31-2.06) | |
Chronic renal insufficiency (n = 63) | 74 ± 30* | 186 ± 79* | 146 ± 72 | 0.83 ± 0.3* |
(15-140) | (66-504) | (52-416) | (0.31-1.9) | |
Acute inflammatory states (n = 15) | 40 ± 12* | 310 ± 140* | 269 ± 90* | 0.94 ± 0.27 |
(15-59) | (123-611) | (120-424) | (0.42-1.6) | |
Major surgery (n = 24) | ||||
Before | 83 ± 27 | 142 ± 53 | 162 ± 77 | 1.16 ± 0.36 |
(48-141) | (72-293) | (60-392) | (0.44-1.39) | |
After 4 days | 58 ± 27* | 201 ± 95* | 185 ± 75‡ | 0.98 ± 0.39† |
(18-131) | (95-300) | (72-369) | (0.90-1.62) |
All values are expressed in percentage of average normal plasma.
Results are given as mean ± SD with observed ranges between parentheses.
For each condition and measurement, statistically significant differences are shown in comparison with controls group as defined in “Results.”
P < .001.
P < .01.
P < .05.